Skip to main content
padlock icon - secure page this page is secure

Breviscapine ameliorates CCl4induced liver injury in mice through inhibiting inflammatory apoptotic response and ROS generation

Buy Article:

$42.00 + tax (Refund Policy)

Acute liver injury is characterized by fibrosis, inflammation and apoptosis, leading to liver failure, cirrhosis or cancer and affecting the clinical outcome in the long term. However, no effective therapeutic strategy is currently available. Breviscapine, a mixture of flavonoid glycosides, has been reported to have multiple biological functions. The present study aimed to investigate the effects of breviscapine on acute liver injury induced by CCl4 in mice. C57BL/6 mice were subjected to intraperitoneal injection with CCl4 for 8 weeks with or without breviscapine (15 or 30 mg/kg). Mice treated with CCl4 developed acute liver injury, as evidenced by histological analysis, Masson trichrome and Sirius Red staining, accompanied with elevated levels of alanine aminotransferase and aspartate aminotransferase. Furthermore, increases in proinflammatory cytokines, chemokines and apoptotic factors, including caspase3 and poly(ADP ribose) polymerase2 (PARP2), were observed. Breviscapine treatment significantly and dosedependently reduced collagen deposition and the fibrotic area. Inflammatory cytokines were downregulated by breviscapine through inactivating Tolllike receptor 4/nuclear factor-κB signaling pathways. In addition, coadministration of breviscapine with CCl4 decreased the apoptotic response by enhancing Bcell lymphoma-2 (Bcl2) levels, while reducing Bcl2associated X protein, apoptotic protease activating factor 1, caspase3 and PARP activity. Furthermore, CCl4induced oxidative stress was blocked by breviscapine through improving antioxidants and impeding mitogenactivated protein kinase pathways. The present study highlighted that breviscapine exhibited liverprotective effects against acute hepatic injury induced by CCl4 via suppressing inflammation and apoptosis.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Department of Hepatobiliary Surgery, Beijing ChaoYang Hospital Affiliated to Capital University of Medical Science, Beijing 100000, P.R. China

Publication date: January 1, 2018

More about this publication?
  • The International Journal of Molecular Medicine is a monthly, peer-reviewed journal devoted to the publication of high quality studies related to the molecular mechanisms of human disease. The journal welcomes research on all aspects of molecular and clinical research, ranging from biochemistry to immunology, pathology, genetics, human genomics, microbiology, molecular pathogenesis, molecular cardiology, molecular surgery and molecular psychology.

    The International Journal of Molecular Medicine aims to provide an insight for researchers within the community in regard to developing molecular tools and identifying molecular targets for the diagnosis and treatment of a diverse number of human diseases.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more